Indexed by Science Citation Index (SciSearch), International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate

ISSN: 1596-5996 (print); 1596-9827 (electronic)-

Home | Back Issues | Current Issue | Review manuscript | Submit manuscript

 
 

This Article

 

Abstract

 

Full-Text (PDF)

 

Table of contents
 

Comments

 

Letters

 

Comments to Editor

 

e-mail Alert

 

Sign Up

 

Original Research Article

Safety of Oral Clemastine – Analysis of Data from Spontaneous Reporting System in Poland

 

Stanisław Han1, Katarzyna Karłowicz-Bodalska1, Katarzyna Miśkiewicz2, Elżbieta Kutycka3 and Ernest Kuchar2*

1Department of Industrial Pharmacy, 2Department of Pediatric Infectious Diseases, Wroclaw Medical University, Poland, 3Pharmacovigilance Department, PPF HASCO-LEK S.A. Wroclaw, Poland

 

*For correspondence: Email: ernest.kuchar@gmail.com; Tel: +48717703156

 

Received: 11 October 2013                                                                   Revised accepted: 23 June 2014

 

Tropical Journal of Pharmaceutical Research, December 2014; 13(12): 2115-2118

http://dx.doi.org/10.4314/tjpr.v13i12.24   

Abstract

 

Purpose: To analyse the safety of oral clemastine marketed in Poland based on spontaneous adverse event reporting system.

Methods: We analyzed sales volume and data obtained from the monitoring of spontaneous reports on the adverse effects of Clemastinum Hasco tablets (1.0 mg) and Clemastinum Hasco syrup (0.1 mg/mL) received by the manufacturer (PPF HASCO-LEK S.A. Wroclaw, Poland) and National Monitoring Centre in Warsaw in the period January 2007 to June 2012. The Polish system is mainly based on written reports voluntarily submitted by healthcare professionals.

Results:  A total of 2,089,717 units of Clemastinum Hasco tablets 1.0 mg and 1,965,340 units of Clemastinum Hasco syrup 0.1 mg/mL were marketed during the period analyzed. Only one spontaneous report on clemastine was registered in the period analyzed.

Conclusion: Oral clemastine is a safe medication, rarely causing adverse effects; Nevertheless, the existing spontaneous monitoring system for adverse effects in Poland may not be sensitive enough and therefore, needs improvement.

 

Keywords: Clemastine, Adverse drug reactions, Pharmoepidemiology, Drug safety, Pharmacovigilance, Reporting system

Copyright@2002-2010. Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City. All rights reserved.

Powered by Poracom E-mail: jmanager@poracom.net